Abstract
This article explains the mechanisms underlying choices of pharmacotherapy for hypoxic-ischemic insults of both preterm and term babies. Some preclinical data are strong enough that clinical trials are now underway. Challenges remain in deciding the best combination therapies for each age and insult.
Keywords:
Brain injury; Hypoxic-ischemic encephalopathy; Preconditioning; Prematurity.
Published by Elsevier Inc.
MeSH terms
-
Acetylcysteine / therapeutic use
-
Allopurinol / therapeutic use
-
Antioxidants / therapeutic use*
-
Ascorbic Acid / therapeutic use
-
Biopterins / analogs & derivatives
-
Biopterins / therapeutic use
-
Erythropoietin / therapeutic use
-
Excitatory Amino Acid Antagonists / therapeutic use*
-
Free Radical Scavengers / therapeutic use*
-
Fructose / analogs & derivatives
-
Fructose / therapeutic use
-
Humans
-
Hypoxia-Ischemia, Brain / drug therapy
-
Hypoxia-Ischemia, Brain / prevention & control*
-
Infant, Extremely Premature
-
Infant, Newborn
-
Infant, Premature
-
Infant, Premature, Diseases / drug therapy
-
Infant, Premature, Diseases / prevention & control*
-
Melatonin / therapeutic use
-
Memantine / therapeutic use
-
Neuroprotective Agents / therapeutic use*
-
Nitric Oxide Synthase Type III / antagonists & inhibitors
-
Resveratrol
-
Stilbenes / therapeutic use
-
Topiramate
-
Vitamin E / therapeutic use
-
Xenon / therapeutic use
Substances
-
Antioxidants
-
Excitatory Amino Acid Antagonists
-
Free Radical Scavengers
-
Neuroprotective Agents
-
Stilbenes
-
Topiramate
-
Erythropoietin
-
Vitamin E
-
Biopterins
-
Fructose
-
Xenon
-
Allopurinol
-
Nitric Oxide Synthase Type III
-
sapropterin
-
Melatonin
-
Ascorbic Acid
-
Resveratrol
-
Memantine
-
Acetylcysteine